Silo Pharma Reports Positive Results from PTSD Study

Silo Pharma, Inc. (Nasdaq: SILO) has announced positive data from its recent pharmacokinetic (PK) study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD). Silo Pharma is conducting preclinical studies of SPC-15 in collaboration with Columbia University under a sponsored research agreement and option.

Commenting on the positive results, Silo CEO Eric Weisblum, said, “Our evaluation of the PK profile for SPC-15 indicates effective and consistent exposure from intranasal administration of the drug. We believe these study results will be substantially replicated in humans.”

SPC-15 has previously demonstrated rapid absorption with good exposure over a full 24-hour period, and optimal once-per-day human intranasal dosing has been determined by these studies.

If clinically successful, SPC-15 could qualify for the FDA’s 505(b)(2) regulatory pathway for drug approval. Silo Pharma is conducting preclinical studies of SPC-15 in collaboration with Columbia University under a sponsored research agreement and option.

About Silo Pharma

Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silo’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. For more information, visit www.silopharma.com and connect on social media at LinkedIn, X, and Facebook.

 

 

Share This Article

 

About the Author

Silo Pharma Reports Positive Results from PTSD Study

Catie Corcoran

Biotech Editor